Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants. [PDF]
Antimicrob Agents ChemotherFosmanogepix [FMGX, APX001; active form: manogepix (MGX), APX001A] is a first-in-class, intravenous (IV)/oral antifungal currently being evaluated for invasive fungal disease treatment.
Hodges MR +6 more
europepmc +2 more sources
Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens
Journal of Fungi, 2022 Invasive fungal infections have mortality rates of 30–90%, depending on patient co-morbidities and the causative pathogen. The frequent emergence of drug resistance reduces the efficacy of currently approved treatment options, highlighting an urgent need
Sean D. Liston +4 more
doaj +1 more source
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician. [PDF]
, 2023 Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-hospital morbidity and mortality. The limited number of antifungal drug classes and the emergence of multi-resistant Candida species, such as Candida auris and ...
Lamoth, F.
core +1 more source
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
APMIS, Volume 131, Issue 11, Page 654-667, November 2023., 2023 The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID‐19) infection.
Sarah Gaffney +4 more
wiley +1 more source
Internal Medicine Journal, Volume 53, Issue 8, Page 1489-1491, August 2023., 2023 Abstract Scedosporium and Lomentospora species are environmental moulds that are virulent in immunocompromised hosts and rarely cause bloodstream infection (BSI). Patients with Scedosporium and Lomentospora species BSI were identified by the state public laboratory service in Queensland, Australia, over a 20‐year period.
Adam G. Stewart +5 more
wiley +1 more source
Antifungal chemotherapies and immunotherapies for the future
Parasite Immunology, Volume 45, Issue 2, February 2023., 2023 Abstract Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response.
Darius Armstrong‐James
wiley +1 more source
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial [PDF]
, 2023 Safety; Antifungal; CandidaemiaSeguridad; Antifúngico; CandidemiaSeguretat; Antifúngic; CandidèmiaBackground Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including ...
aoun, mickael +6 more
core +1 more source
A Bibliometric Review on Candida auris of the First Fifteen Years of Research (2009‐2023)
BioMed Research International, Volume 2023, Issue 1, 2023., 2023 Introduction. Candida auris is a relatively novel pathogen first described in 2009 in Japan. It has increased its presence worldwide, becoming a public health concern due to its innate resistance to antifungals and outbreak potential. Methods.
Hiram Villanueva-Lozano +5 more
wiley +1 more source
Clinical efficacy and safety of a novel antifungal, Fosmanogepix, in patients with candidemia caused by Candida auris : results from a Phase 2 trial [PDF]
, 2023 DATA AVAILABILITY: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified ...
Bien, Paul A. +9 more
core +1 more source
Candida auris: a decade of understanding of an enigmatic pathogenic yeast [PDF]
, 2020 Candida auris is an enigmatic yeast that continues to stimulate interest within the mycology community due its rapid and simultaneous emergence of distinct clades.
Brown, Jason +4 more
core +2 more sources